Cardiometabolic News and Research

RSS

Endocannabinoid system shows promise in combating obesity

As the obesity epidemic grows in the United States, the medical community is faced with the significant challenge of properly treating patients before complications such as heart disease arise.

3 May 2006

Forget the bathroom scales and get out the tape measure!

A new study has found that waist measurements are a better indicator of cardiovascular disease (CVD) than body mass index (BMI).

16 Mar 2006

Rimonabant produces sustained weight loss long term

Use of the weight-loss medication rimonabant produced modest yet sustained weight loss after 2 years, and improved HDL cholesterol and triglyceride levels, according to a study in the February 15 issue of JAMA: The Journal of the American Medical Association.

17 Feb 2006

Rimonabant study shows significant improvements in HbA1c and cardiometabolic risk factors in people with type 2 diabetes

The reported results of a one-year phase III study in 1045 people with type 2 diabetes treated with rimonabant, the first in a new class of therapeutic agents called selective CB1 Blockers, were that rimonabant 20 mg significantly improved HbA1c (a measure of blood sugar control), dyslipidemia (abnormal levels of fat in the blood), and systolic blood pressure with a concomitant substantial reduction in abdominal obesity in people with type 2 diabetes treated with oral anti-diabetic medications and requiring further control.

12 Jun 2005